|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
2
|
Ries LAG, Melbert D, Krapcho M, Stinchcomb
DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ,
Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M and Edwards
BK: SEER Cancer Statistics Review, 1975–2005. National Cancer
Institute; Bethesda, MD: 2008
|
|
3
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: recent
advances and future directions. Oncologist. 13(Suppl 1): 5–13.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanna N, Shepherd FA, Fossella FV, Pereira
JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,
Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold
C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr: Randomized phase
III trial of pemetrexed versus docetaxel in patients with
non-small-cell lung cancer previously treated with chemotherapy. J
Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S,
Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara
D: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ciuleanu T, Brodowicz T, Zielinski C, Kim
JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V,
Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson
P, John WJ, Krejcy K and Belani CP: Maintenance pemetrexed plus
best supportive care versus placebo plus best supportive care for
non-small-cell lung cancer: a randomised, double-blind, phase 3
study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen JS, Chao Y, Bang YJ, Roca E, Chung
HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP, Shen LJ and Linn C:
A phase I/II and pharmacogenomic study of pemetrexed and cisplatin
in patients with unresectable, advanced gastric carcinoma.
Anticancer Drugs. 21:777–784. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen CY, Chang YL, Shih JY, Lin JW, Chen
KY, Yang CH, Yu CJ and Yang PC: Thymidylate synthase and
dihydrofolate reductase expression in non-small cell lung
carcinoma: The association with treatment efficacy of pemetrexed.
Lung Cancer. 74:132–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lorusso D, Ferrandina G, Pignata S,
Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A
and Scambia G: Evaluation of pemetrexed (Alimta, LY231514) as
second-line chemotherapy in persistent or recurrent carcinoma of
the cervix: the CERVIX 1 study of the MITO (Multicentre Italian
Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann
Oncol. 21:61–66. 2010. View Article : Google Scholar
|
|
10
|
Mazzer M, Zanon E, Foltran L, De Pauli F,
Cardellino G, Iaiza E, Ermacora P, Aprile G and Fasola G:
Second-line pemetrexed-oxaliplatin combination for advanced
pancreatic adenocarcinoma. J Clin Oncol. 27(Suppl): e155972009.
|
|
11
|
Atkins JN, Jacobs SA, Wieand HS, Smith RE,
John WJ, Colangelo LH, Vogel VG, Kuebler JP, Cescon TP, Miller BJ,
Geyer CE Jr and Wolmark N: Pemetrexed/oxaliplatin for first-line
treatment of patients with advanced colorectal cancer: A phase II
trial of the National Surgical Adjuvant Breast and Bowel Project
Foundation Research Program. Clin Colorectal Cancer. 5:181–187.
2005. View Article : Google Scholar
|
|
12
|
Pippen J, Elias AD, Neubauer M, Stokoe C,
Vaughn LG, Wang Y, Orlando M, Shonukan O, Muscato J, O’Shaughnessy
JA and Gralow J: A phase II trial of pemetrexed and gemcitabine in
patients with metastatic breast cancer who have received prior
taxane therapy. Clin Breast Cancer. 10:148–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Celio L, Sternberg CN, Labianca R, La
Torre I, Amoroso V, Barone C, et al: Pemetrexed in combination with
oxaliplatin as a first-line therapy for advanced gastric cancer: a
multi-institutional phase II study. Ann Oncol. 20:1062–1067. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martinez-Balibrea E, Manzano JL,
Martinez-Cardus A, Moran T, Cirauqui B, Catot S, Taron M and Abad
A: Combined analysis of genetic polymorphisms in thymidylate
synthase, uridine diphosphate glucoronosyltransferase and X-ray
cross complementing factor 1 genes as a prognostic factor in
advanced colorectal cancer patients treated with 5-fluorouracil
plus oxaliplatin or irinotecan. Oncol Rep. 17:637–645. 2007.
|
|
15
|
Urano W, Taniguchi A, Yamanaka H, Tanaka
E, Nakajima H, Matsuda Y, Akama H, Kitamura Y and Kamatani N:
Polymorphisms in the methylenetetrahydrofolate reductase gene were
associated with both the efficacy and the toxicity of methotrexate
used for the treatment of rheumatoid arthritis, as evidenced by
single locus and haplotype analyses. Pharmacogenetics. 12:183–190.
2002. View Article : Google Scholar
|
|
16
|
Smit EF, Burgers SA, Biesma B, Smit HJ,
Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van
Zandwijk N and Groen HJ: Randomized phase II and pharmacogenetic
study of pemetrexed compared with pemetrexed plus carboplatin in
pretreated patients with advanced non-small cell lung cancer. J
Clin Oncol. 27:2038–2045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Argiris A, Karamouzis MV, Gooding WE,
Branstetter BF, Zhong S, Raez LE, Savvides P and Romkes M: Phase II
trial of pemetrexed and bevacizumab in patients with recurrent or
meta-static head and neck cancer. J Clin Oncol. 29:1140–1145. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Adjei AA, Salavaggione OE, Mandrekar SJ,
Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE and Adjei AA:
Correlation between polymorphisms of the reduced folate carrier
gene (SLC19A1) and survival after pemetrexed-based therapy
in non-small cell lung cancer. J Thorac Oncol. 5:1346–1353.
2010.PubMed/NCBI
|
|
19
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian M and Gwyther SG: New guidelines to evaluate
the response to treatment in solid tumors: European Organization
for Research and Treatment of Cancer, National Cancer Institute of
the United States, National Cancer Institute of Canada. J Natl
Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
|
|
20
|
Mandola MV, Stoehlmacher J, Muller-Weeks
S, Cesarone G, Yu MC and Lenz HJ: 2898–2904. 2003.
|
|
21
|
Kawakami K and Watanabe G: Identification
and functional analysis of single nucleotide polymorphism in the
tandem repeat sequence of thymidylate synthase gene. Cancer Res.
63:6004–6007. 2003.PubMed/NCBI
|
|
22
|
Fernández - Contreras ME, Sánchez -
Prudencio S, Sánchez-Hernández JJ, García de Paredes ML, Gisbert
JP, Roda-Navarro P and Gamallo C: Thymidylate synthase expression
pattern, expression level and single nucleotide polymorphism are
predictors for disease-free survival in patients of colorectal
cancer treated with 5-fluorouracil. Int J Oncol. 28:1303–1310.
2006.
|
|
23
|
Fariña-Sarasqueta A, Gosens MJ, Moerland
E, et al: TS gene polymorphisms are not good markers of
response to 5-FU therapy in stage III colon cancer patients. Cell
Oncol (Dordr). 34:327–335. 2011.
|
|
24
|
Vignoli M, Nobili S, Napoli C, et al:
Thymidylate synthase expression and genotype have no major impact
on the clinical outcome of colorectal cancer patients treated with
5-fluorouracil. Pharmacol Res. 64:242–248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ruzzo A, Graziano F, Loupakis F, Rulli E,
Canestrari E, Santini D, et al: Pharmacogenetic profiling in
patients with advanced colorectal cancer treated with first-line
FOLFOX-4 chemotherapy. J Clin Oncol. 25:1247–1254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marcuello E, Altés A, Menoyo A, Rio ED and
Baiget M: Methylenetetrahydrofolate reductase gene polymorphisms:
genomic predictors of clinical response to fluoropyrimidine-based
chemotherapy? Cancer Chemother Pharmacol. 57:835–840. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Frosst P, Blom HJ, Milos R, Goyette P,
Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LA,
van den Heuvel LP, et al: A candidate genetic risk factor for
vascular disease: a common mutation in methylenetetrahydrofolate
reductase. Nat Genet. 10:111–113. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jakobsen A, Nielsen JN, Gyldenkerne N and
Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate
reductase gene polymorphism in normal tissue as predictors of
fluorouracil sensitivity. J Clin Oncol. 23:1365–1369. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ruzzo A, Graziano F, Kawakami K, Watanabe
G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R,
Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P,
Cascinu S, Giustini L, Tonini G and Magnani M: Pharmacogenetic
profiling and clinical outcome of patients with advanced gastric
cancer treated with palliative chemotherapy. J Clin Oncol.
24:1883–1891. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boige V, Mendiboure J, Pignon JP, Loriot
MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre
D, Miran I, Mulot C, Ducreux M, Beaune P and Laurent-Puig P:
Pharmacogenetic assessment of toxicity and outcome in patients with
metastatic colorectal cancer treated with LV5FU2, FOLFOX, and
FOLFIRI: FFCD 2000-05. J Clin Oncol. 28:2556–2564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goekkurt E, Al-Batran SE, Hartmann JT,
Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G and
Stoehlmacher J: Pharmacogenetic analyses of a phase III trial in
metastatic gastroesophageal adenocarcinoma with fluorouracil and
leucovorin plus either oxaliplatin or cisplatin: a study of the
arbeitsgemeinschaft internistische onkologie. J Clin Oncol.
27:2863–2873. 2009. View Article : Google Scholar
|
|
33
|
Zintzaras E, Ziogas DC, Kitsios GD,
Papathanasiou AA, Lau J and Raman G: MTHFR gene
polymorphisms and response to chemotherapy in colorectal cancer: a
meta analysis. Pharmacogenomics. 10:1285–1294. 2009. View Article : Google Scholar
|
|
34
|
Adjei AA, Mandrekar SJ, Dy GK, Molina JR,
Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild
SE and Zinner RG: A phase II trial of pemetrexed plus bevacizumab
for second-line therapy of patients with advanced non-small cell
lung cancer (NSCLC): an NCCTG and SWOG Study N0426. J Clin Oncol.
28:614–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
